INR 43.14
(1.03%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 288.79 Million INR | 104.76% |
2022 | 141.04 Million INR | 644.48% |
2021 | 18.94 Million INR | -88.93% |
2020 | 171.09 Million INR | -37.74% |
2019 | 274.81 Million INR | 160.16% |
2018 | 105.63 Million INR | -3.86% |
2017 | 109.87 Million INR | 20.16% |
2016 | 91.43 Million INR | -30.86% |
2015 | 132.25 Million INR | 147.59% |
2014 | 53.41 Million INR | -20.7% |
2013 | 67.35 Million INR | 9.87% |
2012 | 61.3 Million INR | -15.7% |
2011 | 72.72 Million INR | 97.67% |
2010 | 36.79 Million INR | -56.84% |
2009 | 85.24 Million INR | 18.42% |
2008 | 71.98 Million INR | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | -182.02 Million INR | -163.03% |
2023 Q4 | 288.79 Million INR | 0.0% |
2023 Q3 | - INR | -100.0% |
2023 FY | 288.79 Million INR | 104.76% |
2023 Q1 | - INR | -100.0% |
2023 Q2 | 245.45 Million INR | 0.0% |
2022 Q2 | 160.32 Million INR | 0.0% |
2022 Q3 | - INR | -100.0% |
2022 Q4 | 141.04 Million INR | 0.0% |
2022 FY | 141.04 Million INR | 644.48% |
2022 Q1 | - INR | -100.0% |
2021 Q1 | - INR | -100.0% |
2021 Q2 | 211.7 Million INR | 0.0% |
2021 Q3 | - INR | -100.0% |
2021 Q4 | 18.94 Million INR | 0.0% |
2021 FY | 18.94 Million INR | -88.93% |
2020 Q2 | 182.23 Million INR | 0.0% |
2020 Q1 | - INR | -100.0% |
2020 Q3 | - INR | -100.0% |
2020 FY | 171.09 Million INR | -37.74% |
2020 Q4 | 171.09 Million INR | 0.0% |
2019 FY | 274.81 Million INR | 160.16% |
2019 Q1 | - INR | -100.0% |
2019 Q2 | 308.55 Million INR | 0.0% |
2019 Q3 | - INR | -100.0% |
2019 Q4 | 274.81 Million INR | 0.0% |
2018 Q4 | 105.63 Million INR | 0.0% |
2018 FY | 105.63 Million INR | -3.86% |
2018 Q3 | - INR | -100.0% |
2018 Q2 | 129.1 Million INR | 0.0% |
2018 Q1 | - INR | -100.0% |
2017 FY | 109.87 Million INR | 20.16% |
2017 Q2 | 141.41 Million INR | 0.0% |
2017 Q4 | 109.87 Million INR | 0.0% |
2017 Q1 | - INR | -100.0% |
2017 Q3 | - INR | -100.0% |
2016 Q2 | 74.48 Million INR | 0.0% |
2016 Q1 | - INR | -100.0% |
2016 Q4 | 91.43 Million INR | 0.0% |
2016 FY | 91.43 Million INR | -30.86% |
2016 Q3 | - INR | -100.0% |
2015 Q2 | 52.45 Million INR | 0.0% |
2015 Q4 | 132.25 Million INR | 0.0% |
2015 FY | 132.25 Million INR | 147.59% |
2015 Q1 | - INR | -100.0% |
2015 Q3 | - INR | -100.0% |
2014 Q1 | 64.65 Million INR | -4.01% |
2014 Q3 | - INR | -100.0% |
2014 Q2 | 63.47 Million INR | -1.83% |
2014 Q4 | 53.41 Million INR | 0.0% |
2014 FY | 53.41 Million INR | -20.7% |
2013 Q3 | - INR | -100.0% |
2013 Q1 | - INR | -100.0% |
2013 FY | 67.35 Million INR | 9.87% |
2013 Q2 | 60.87 Million INR | 0.0% |
2013 Q4 | 67.35 Million INR | 0.0% |
2012 Q4 | 61.3 Million INR | 5.12% |
2012 Q2 | 58.23 Million INR | 0.0% |
2012 FY | 61.3 Million INR | -15.7% |
2012 Q3 | 58.32 Million INR | 0.15% |
2011 FY | 72.72 Million INR | 97.67% |
2011 Q4 | 72.72 Million INR | 0.0% |
2010 FY | 36.79 Million INR | -56.84% |
2009 FY | 85.24 Million INR | 18.42% |
2008 Q4 | 71.98 Million INR | 0.0% |
2008 FY | 71.98 Million INR | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Alembic Pharmaceuticals Limited | 16.27 Billion INR | 98.225% |
Hester Biosciences Limited | 3.59 Billion INR | 91.966% |
Aarti Drugs Limited | 11.5 Billion INR | 97.49% |
Aarti Pharmalabs Limited | 8.25 Billion INR | 96.5% |
Albert David Limited | 1.15 Billion INR | 74.889% |
Alembic Limited | 1.43 Billion INR | 79.834% |
Alkem Laboratories Limited | 48.6 Billion INR | 99.406% |
Bafna Pharmaceuticals Limited | 652.27 Million INR | 55.725% |
Bajaj HealthCare Limited | 4.86 Billion INR | 94.067% |
Brooks Laboratories Limited | 248.6 Million INR | -16.17% |
Eris Lifesciences Limited | 38.26 Billion INR | 99.245% |
FDC Limited | 3.7 Billion INR | 92.214% |
Glenmark Life Sciences Limited | 5.18 Billion INR | 94.426% |
Gufic Biosciences Limited | 5.59 Billion INR | 94.843% |
Hikal Limited | 12.99 Billion INR | 97.778% |
Ind-Swift Limited | 13.45 Billion INR | 97.853% |
Innova Captab Limited | 4.89 Billion INR | 94.106% |
IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | 95.437% |
Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | 2.683% |
Jubilant Pharmova Limited | 61.27 Billion INR | 99.529% |
Lincoln Pharmaceuticals Limited | 1.07 Billion INR | 73.124% |
Lupin Limited | 96.23 Billion INR | 99.7% |
Mangalam Drugs & Organics Limited | 1.97 Billion INR | 85.387% |
Medico Remedies Limited | 438.24 Million INR | 34.101% |
Morepen Laboratories Limited | 4.45 Billion INR | 93.524% |
Nectar Lifesciences Limited | 11.21 Billion INR | 97.426% |
Orchid Pharma Limited | 3.84 Billion INR | 92.487% |
Procter & Gamble Health Limited | 2.56 Billion INR | 88.724% |
RPG Life Sciences Limited | 1.38 Billion INR | 79.076% |
Kilitch Drugs (India) Limited | 643.88 Million INR | 55.147% |
Sigachi Industries Limited | 2.53 Billion INR | 88.591% |
Solara Active Pharma Sciences Limited | 14.09 Billion INR | 97.951% |
Suven Pharmaceuticals Limited | 2.03 Billion INR | 85.803% |
Themis Medicare Limited | 1.88 Billion INR | 84.699% |
Unichem Laboratories Limited | 8.06 Billion INR | 96.421% |
Vaishali Pharma Limited | 371.16 Million INR | 22.191% |
Wanbury Limited | 3.15 Billion INR | 90.848% |
Windlas Biotech Limited | 1.76 Billion INR | 83.616% |
ZIM Laboratories Limited | 2.08 Billion INR | 86.121% |
Ind-Swift Laboratories Limited | 2.28 Billion INR | 87.386% |
Ipca Laboratories Limited | 33.74 Billion INR | 99.144% |
Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 99.843% |
Venus Remedies Limited | 1.39 Billion INR | 79.265% |
Sakar Healthcare Limited | 1.26 Billion INR | 77.139% |
Aurobindo Pharma Limited | 152.2 Billion INR | 99.81% |
Divi's Laboratories Limited | 18.99 Billion INR | 98.479% |
AstraZeneca Pharma India Limited | 3.66 Billion INR | 92.112% |
Mankind Pharma Limited | 23.87 Billion INR | 98.79% |
Sequent Scientific Limited | 8.27 Billion INR | 96.51% |
Laurus Labs Limited | 42.71 Billion INR | 99.324% |
Neuland Laboratories Limited | 5.49 Billion INR | 94.748% |
J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | 97.303% |
Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 99.556% |
Zydus Lifesciences Limited | 71.79 Billion INR | 99.598% |
Amrutanjan Health Care Limited | 783.82 Million INR | 63.155% |
Wockhardt Limited | 39.87 Billion INR | 99.276% |
Bal Pharma Limited | 2.51 Billion INR | 88.5% |
Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 99.73% |
Bliss GVS Pharma Limited | 2.1 Billion INR | 86.305% |
Par Drugs and Chemicals Limited | 159.79 Million INR | -80.735% |
Caplin Point Laboratories Limited | 3.5 Billion INR | 91.762% |
Shilpa Medicare Limited | 12.93 Billion INR | 97.767% |
Valiant Laboratories Limited | 1.05 Billion INR | 72.71% |
Ajanta Pharma Limited | 10.71 Billion INR | 97.304% |
Aarey Drugs & Pharmaceuticals Limited | 1.72 Billion INR | 83.231% |
Granules India Limited | 22.95 Billion INR | 98.742% |
Medicamen Biotech Limited | 940.36 Million INR | 69.289% |
Syncom Formulations (India) Limited | 1.16 Billion INR | 75.215% |
Piramal Enterprises Limited | 560.47 Billion INR | 99.948% |
Torrent Pharmaceuticals Limited | 82.05 Billion INR | 99.648% |
NATCO Pharma Limited | 10.53 Billion INR | 97.258% |
Suven Life Sciences Limited | 148.62 Million INR | -94.319% |
Krebs Biochemicals & Industries Limited | 2.97 Billion INR | 90.289% |
Strides Pharma Science Limited | 37.68 Billion INR | 99.234% |
Indoco Remedies Limited | 10.34 Billion INR | 97.208% |
Alpa Laboratories Limited | 307.12 Million INR | 5.966% |
Lasa Supergenerics Limited | 541.92 Million INR | 46.709% |
Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | 92.581% |